Target intelligence / Profile preview

Otoferlin (OTOF)

Target
OTOF
Molecular classification
Other (ferlin family, multi–C2 domain, single-pass transmembrane protein)
01

Overview

Otoferlin is a large (~1,997 amino acids) single-pass transmembrane protein of the ferlin family that contains multiple Ca2+-binding C2 domains and a C-terminal membrane anchor; it functions as a key Ca2+ sensor for synaptic vesicle exocytosis at inner hair cell ribbon synapses, where several C2 domains (except C2A) bind Ca2+ and phospholipids to promote and regulate SNARE-mediated membrane fusion and vesicle replenishment; loss-of-function mutations in the OTOF gene cause DFNB9 auditory synaptopathy with severe-to-profound sensorineural deafness, making OTOF a validated therapeutic target for gene replacement approaches in the inner ear

Other names
OTOFFer1L2ferlin family memberDFNB9-related protein
02

Mechanism of action

For otoferlin itself: acts as a Ca2+ sensor through several C2 domains to regulate and stimulate SNARE-dependent membrane fusion/exocytosis in hair cells. For investigational gene therapies: gene replacement delivering functional OTOF to restore hair cell synaptic transmission.

03

Biological functions

Synaptic vesicle exocytosis in inner hair cellsCalcium-dependent signaling via multiple C2 domainsVesicle membrane targeting through phospholipid interactions (e.g., PIP2, phosphatidylserine)Putative regulation of SNARE-mediated membrane fusion
04

Disease associations

Neurodegenerative disease: auditory synaptopathy and nonsyndromic recessive deafness DFNB9 caused by OTOF mutationsOther: congenital or early-onset severe-to-profound sensorineural hearing loss due to inner hair cell synaptic dysfunction
05

Safety considerations

Therapeutic challenge: very large coding sequence (~6 kb) complicates single‑vector AAV delivery; dual‑AAV strategies needed, posing risks of incomplete reconstitutionOff-target or variable expression risks with inner-ear gene therapy; need for precise inner hair cell targeting and dose control (general to AAV inner ear therapies)Potential immune responses to AAV capsids or transgene product (general gene therapy considerations)
06

Interacting drugs

None known
07

Biomarkers

Genetic testing for biallelic pathogenic OTOF variants to diagnose DFNB9 and select candidates for gene therapyAuditory brainstem responses (ABR) absent with preserved otoacoustic emissions indicating auditory synaptopathy in OTOF-related disease

Beyond the preview

Go deeper on Otoferlin (OTOF).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Otoferlin (OTOF).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call